What's Going On With Ocugen's Stock?

Ocugen, Inc. OCGN shares are trading higher amid heightened interest in the stock from retail traders on social media.

According to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.

Traders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech's COVAXIN. NOTE: Ocugen is a partner on COVAXIN.

Ocugen's average session volume is 21.45 million over a 100-day period. At publication time, Monday's trading volume had already exceeded 83.62 million, according to data from Benzinga Pro.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.

Ocugen's stock was trading about 16% higher at $13.73 per share on Monday at the time of publication. The stock has a 52-week high of $18.77 and a 52-week low of $0.25.